


Accepted Manuscript

Participant eligibility, recruitment and retention in pragmatic trials

Katrien Oude Rengerink, Shona Kalkman, Susan Collier, Antonio Ciaglia, Sally D. Worsley, Alison Lightbourne, Laurent Eckert, Rolf H.H. Groenwold, Diederick E. Grobbee, Elaine A. Irving



PII: S0895-4356(17)30480-8

DOI: [10.1016/j.jclinepi.2016.12.021](https://doi.org/10.1016/j.jclinepi.2016.12.021)

Reference: JCE 9396

To appear in: *Journal of Clinical Epidemiology*

Received Date: 16 May 2016

Revised Date: 2 December 2016

Accepted Date: 12 December 2016

Please cite this article as: Oude Rengerink K, Kalkman S, Collier S, Ciaglia A, Worsley SD, Lightbourne A, Eckert L, Groenwold RHH, Grobbee DE, Irving EA, on behalf of Work Package 3 of the GetReal consortium, Participant eligibility, recruitment and retention in pragmatic trials, *Journal of Clinical Epidemiology* (2017), doi: 10.1016/j.jclinepi.2016.12.021.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Participant eligibility, recruitment and retention in pragmatic trials**

2

3 Katrien Oude Rengerink¹, Shona Kalkman¹, Susan Collier², Antonio Ciaglia,³ Sally D. Worsley,⁴ Alison
4 Lightbourne³, Laurent Eckert,⁵ Rolf H.H. Groenwold,¹ Diederick E. Grobbee^{1,6}, Elaine A. Irving⁴, on behalf
5 of Work Package 3 of the GetReal consortium

6

7 ¹Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the
8 Netherlands.

9 ²Respiratory Research & Development, GSK, Middlesex, United Kingdom.

10 ³International Alliance of Patients' Organizations, London, United Kingdom.

11 ⁴Real World Study Delivery, GSK Research & Development, Stevenage, United Kingdom.

12 ⁵HEOR Dupilumab-Sanofi, Chilly-Mazarin, France.

13 ⁶Julius Clinical, Zeist, the Netherlands.

14

15 **Word count:** 3619 (Main text)

16

17 **Corresponding author**

18 Katrien Oude Rengerink, MSc, PhD

19 Julius Center for Health Sciences and Primary Care, Room number Str. 6131

20 University Medical Center Utrecht

21 PO Box 85500, 3508 GA Utrecht, the Netherlands

22 Email: k.ouderengerink-2@umcutrecht.nl

23

24

Download English Version:

<https://daneshyari.com/en/article/7519547>

Download Persian Version:

<https://daneshyari.com/article/7519547>

[Daneshyari.com](https://daneshyari.com)